Monday, August 25, 2025

Latest

Canaccord Resumes Coverage On The Valens Company, Issues $6.50 Price Target

This morning Canaccord Genuity resumed coverage on The Valens Company (TSX: VLNS) with a C$6.50 price target and Speculative Buy rating, which is below the analyst estimate mean of C$7. However, the analyst is one of only two to have a strong buy rating on the company.

Canaccord sings high praise for Valens, stating the firm, “has amassed the most diverse manufacturing capabilities within the Canadian cannabis arena,” which Canaccord believes can be used and leveraged into a position of substantial market share in cannabis 2.0, a segment that Canaccord believes to have high medium to long term growth.

To support this argument, the analyst went as far as showcasing the array of extraction methods that Valens currently offers for third-party manufacturing. Currently, Valens has five different extraction types, which are 2-3 more than its competitors. Canaccord says that this diversity, alongside the ability to develop a full brand of products, sets Valens apart from its peers.

The firm then goes on to state that the international markets alongside many exciting developments make Valens a “Catalyst Rich” company. On the international development side, Canaccord says that with C$100m in cash plus the recent hires to find and identify asset purchases, Valens can make a big splash in the international markets. The other catalysts that Canaccord says could happen in the next 12 months include:

  • White-label contracts
  • EU-GMP Certification
  • Accelerated growth in international markets

Canaccord predicts that Valens will more than double their FY2019 revenue, going from C$58.1m to C$139.9m, and will become net income positive at the end of FY2020 with net income coming in around C$5.9m. The firm then sees Valens increasing their revenue by 40% to C$200.5m in FY2021, becoming free cash flow positive which will continue into FY2022 with a further revenue increase of ~38% to C$276.5m, which from FY2019 is an almost 400% increase.


Information for this briefing was found via Sedar and The Valens Company. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

First Majestic Q2 Earnings: Another Record Quarter

Sandstorm Gold Fades Into Royal Gold Merger

Equinox Gold Q2 Earnings: Back On Track

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Equinox Gold: Mercedes Mine Sale Was “A Favourable Sale Price For A Non-Core Asset”

On December 17th, Equinox Gold (TSX: EQX) announced that they reached an agreement to sell...

Sunday, December 26, 2021, 02:14:00 PM

K92: BMO Trims 2022 Production Estimates After Q2 Results

K92 Mining Inc. (TSX: KNT) reported its second quarter production results last week. The company...

Monday, July 18, 2022, 11:30:50 AM

Beyond Meat Sees Analysts Slash Price Targets

Beyond Meat, Inc. (Nasdaq: BYND) recently reported its third quarter results for the period ending...

Sunday, November 20, 2022, 11:12:00 AM

Nutrien Sees Consensus Price Target Improvement Following Raised Guidance

On June 21st, Nutrien (TSX: NTR) raised their first half 2021 earnings per share guidance...

Wednesday, June 23, 2021, 03:36:00 PM

Curaleaf: The Analyst Take On The European Expansion

On April 7th, Curaleaf Holdings (CSE: CURA) announced that they completed $312 million acquisition of...

Friday, April 9, 2021, 11:46:00 AM